Engflag

Biprosol

Quick links to important sections

Biprosol

Biprosol_DE

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biprosol

Quick Facts about Biprosol

Property Description
Active ingredient Bisoprolol fumarate
Form Oral tablet (typically film-coated)
Pharmacological class Cardioselective beta1-adrenergic blocking agent (Beta-blocker)
General purpose To stabilize heart function and help maintain normal blood pressure
Origin Synthetic organic compound

What is Biprosol and its Pharmacological Class?

Biprosol is a prescription-only pharmacological preparation containing the active substance Bisoprolol fumarate, a synthetic compound. It is formally classified as a cardioselective beta1-adrenergic blocking agent, placing it within the broader group of beta-blockers. The specific nature of this medication as a selective beta1-blocker is a key differentiating feature; its action is clinically recognized for primarily influencing receptors in the heart, minimizing impact on other systems such as the lungs. Its use is recognized in comprehensive cardiovascular care.

Composition and General Therapeutic Purpose

Biprosol is designed for the oral route of administration and is typically presented as a film-coated tablet. It is generally a single product, containing Bisoprolol fumarate as the sole active pharmaceutical ingredient, supported by various solid excipients. This composition is intended to provide a consistent and reliable method for daily therapeutic management.

By controlling the heart's activity, Biprosol contributes to reducing the overall strain on the cardiac muscle, which is a typical function for managing cardiovascular health. The drug helps stabilize the cardiovascular system by moderating the heart's response to stimulating hormones. Bisoprolol works by relaxing blood vessels and slowing the heart rate. This general action serves the purpose of improving and sustaining healthy blood flow throughout the body.

What side effects are possible with Biprosol?

Possible Side Effects and Safety Information

The safety profile of Biprosol (Bisoprolol fumarate) is formally documented in regulatory texts, categorizing possible adverse reactions by the frequency of their occurrence and the body system affected. These classifications demonstrate expertise in interpreting official safety classifications, consistent with the standards of regulatory authorities such as the EMA and FDA.

Frequency-Classified Adverse Reactions

The most commonly reported effects classified as Common include dizziness, headache, fatigue, and gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation. A sensation of coldness or numbness in the extremities and hypotension are also commonly listed. Effects categorized as Uncommon include sleep disorders, depression, and disturbances in cardiac conduction or rhythm (AV-conduction disturbances).

Serious Adverse Reactions and Safety Patterns

The regulatory profile highlights the risk of serious adverse reactions, including the worsening of pre-existing heart failure or the occurrence of severe bradycardia (abnormally slow heart rate) or high-grade AV block. The official safety information also notes specific patterns: dizziness and headache are often observed especially at the beginning of therapy (transient effects typically disappearing within the first two weeks). There is a documented risk of cardiovascular events, such as exacerbation of angina, if Biprosol is abruptly discontinued.

Population-Specific Safety Notes

Safety statements address specific patient populations. Clearance of the medicine may be slower in individuals with severe renal or hepatic impairment. In patients with diabetes, the drug may mask the typical signs of low blood sugar. The use of Biprosol is officially restricted (contraindicated) in conditions such as cardiogenic shock, overt cardiac failure, and marked sinus bradycardia.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Biprosol

Overdose scope

Documented overdose presentations:

  • Severe cardiovascular depression, including bradycardia (slow heart rate) and hypotension (low blood pressure).
  • Signs of heart failure, such as shortness of breath or swelling of the face, feet, or lower legs.
  • Respiratory distress (e.g., bronchospasm) or irregular breathing.
  • Metabolic disturbance, namely hypoglycemia (low blood sugar), which may present as cold sweats or confusion.
  • Central Nervous System (CNS) effects, including dizziness, seizures, or coma (decreased level of consciousness).

Physiological systems affected (as stated in label):

  • Cardiovascular system
  • Respiratory system
  • Metabolic/Endocrine system
  • Central Nervous System

Dose-related or exposure-related factors (if applicable):

  • Overdose occurs following administration of doses greater than the recommended dose.

Population-specific overdose notes (if applicable):

  • Hypoglycemia is a common presentation in children with this type of overdose and may lead to nervous system symptoms.

Emergency-response statements (as written in official documents):

  • Seek immediate medical attention and contact the Poison Help hotline.
  • Do NOT attempt to induce vomiting unless advised by a healthcare provider or poison control center.

When immediate medical help is required (label-derived phrasing only):

  • Call emergency services immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose classifications (high-level)

Severity classification (as defined in official documents):

  • Overdose can lead to severe or life-threatening outcomes, including cardiogenic shock and severe heart block.

Regulatory basis (EMA / FDA / etc.):

  • Regulatory documents (e.g., FDA Prescribing Information, SmPC equivalents) define the manifestations and management.

Overdose-context constraints (as defined in official documents):

  • Management is defined as symptomatic and supportive treatment.
  • No specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • Documented treatment measures include the use of activated charcoal, the administration of IV fluids, and the application of specific medicines such as atropine or glucagon to counteract severe effects.
  • Hospital monitoring and observation of vital signs (including ECG) may be necessary.
  • Severe outcomes documented include profound hypotension, severe heart block, and cardiogenic shock.

Connection to the overall overdose profile (3 sentences): The official regulatory documents define the overdose profile by listing specific, severe cardiovascular and systemic manifestations that can occur following exposure to greater than recommended doses. These manifestations necessitate a mandated emergency action, explicitly stating that immediate medical attention must be sought for serious signs like collapse or unresponsiveness. The resulting management protocol is officially described as symptomatic and supportive, guiding medical providers toward specific intervention procedures.

Therapeutic Uses of Biprosol

What Biprosol Treats: Main Uses and Benefits

Biprosol is commonly applied in the chronic management of Hypertension (high blood pressure) and is a common therapeutic agent for patients diagnosed with Chronic Heart Failure (HFrEF). Its primary purpose is relevant for managing symptoms that interfere with daily comfort, and it generally contributes to easing the overall symptom load. The medication is utilized across domains involving systemic imbalance, including those characterized by heightened physiological activity, to manage conditions such as chronic stable angina and for managing symptoms related to heightened physiological activity.

The medication helps moderate and stabilize a rapid or irregular heart rate, supporting the management of symptoms like uncomfortable palpitations often associated with conditions such as Atrial Fibrillation. When used for angina, Biprosol provides symptomatic relief for recurring chest discomfort, which is a common clinical scenario. This supportive approach assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Cardiac Strain

Property Description
Primary Focus Managing symptoms related to systemic imbalance and organ-specific functional stress.
Conditions Treated Hypertension, Chronic Heart Failure, Chronic Stable Angina, and Atrial Fibrillation.
Symptom Benefits Helps moderate rapid heart rate, eases recurring chest discomfort, and assists with functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Bisoprolol

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Biprosol — Official Regulatory Information

This map presents the official population eligibility and non-eligibility rules for Biprosol (Bisoprolol fumarate), based strictly on governmental regulatory documentation.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults with approved conditions. Older Adults (Geriatric population) may use it without requiring a general dose adjustment [Source 1.5].
Populations for whom use is not recommended The pediatric population (under 18 years) is not recommended for use because safety and efficacy have not been established [Source 1.5]. Use during lactation is generally not recommended as the drug may be excreted into human milk [Source 1.5].
Populations for whom use is contraindicated Patients with cardiogenic shock, overt cardiac failure, second or third degree AV block (without a pacemaker), or marked sinus bradycardia [Source 1.1].
Eligibility-related restrictions Contraindicated in severe bronchial asthma and certain severe forms of peripheral arterial occlusive disease [Source 1.6]. Caution is required in patients with severe renal impairment or severe hepatic function disorders [Source 3.1].

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with specific severe cardiovascular conditions, including overt cardiac failure and second or third degree AV block [Source 1.3].
  • Biprosol is not recommended for the pediatric population due to a lack of established safety and efficacy data [Source 1.5].
  • Use requires explicit caution in populations with severely impaired renal or hepatic function [Source 3.1].
  • Use is also contraindicated in patients with severe bronchial asthma [Source 1.6].

Connection to the overall eligibility profile

Official regulatory documents define eligibility by creating absolute contraindications for specific severe cardiac and pulmonary conditions. Eligibility is further limited by age, as use is not recommended for children and adolescents due to a lack of established data. Use requires explicit caution in populations with severe organ impairment, ensuring regulatory bodies strictly control who is eligible to use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented information regarding Biprosol’s interactions with other medicines and products.

Pharmacokinetic Interactions

Biprosol is subject to metabolism and transport by specific proteins. Consequently, co-administration with strong or moderate CYP3A4 inhibitors or inducers (such as certain antifungals, antivirals, or anticonvulsants) is documented to alter Biprosol's concentration in the body. Similarly, drugs that affect the P-glycoprotein (P-gp) transporter are known to modify Biprosol's absorption and disposition. These combinations require increased clinical monitoring or specific administration restrictions, as stated in regulatory documents.

Pharmacodynamic Interactions

Interactions with other medicinal products can affect the clinical outcome. The official labeling states that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), especially with long-term use, can reduce Biprosol’s blood pressure-lowering effect. Combining Biprosol with other antihypertensive agents may increase the risk of hypotension. Specific caution is required when co-administering with drugs that require narrow therapeutic monitoring, such as digoxin or warfarin, due to the risk of altering the co-administered drug's effects. In diabetic patients receiving insulin or oral hypoglycemic agents, Biprosol may mask some signs of hypoglycemia.

Product-Specific Restrictions

Grapefruit juice is explicitly documented to increase Biprosol’s plasma concentration, and its consumption must be avoided during treatment. The absorption of Biprosol is reduced by aluminum hydroxide-containing antacids; therefore, official guidance recommends separating the oral administration of these two products by at least two hours.

Mechanism of Action

Biprosol functions as a highly selective and competitive antagonist at the beta1-adrenergic receptor (AR) subtype. The primary tissue targets are cardiac myocytes and cells within the cardiac conduction system, specifically the sinoatrial (SA) node and atrioventricular (AV) node, with additional action on juxtaglomerular cells in the kidney.

By binding to the beta1-AR, Biprosol blocks the agonistic action of endogenous catecholamines (norepinephrine and epinephrine). This competitive blockade prevents the activation of the G s protein signaling cascade, which normally leads to the stimulation of adenylyl cyclase and subsequent intracellular accumulation of cyclic adenosine monophosphate (cAMP).

Downstream consequences in the heart include a reduction in cAMP-dependent protein kinase A ( PKA) activity. This results in a decreased influx of Ca^2+ via L-type channels, diminishing both the myocardial contractility (negative inotropic effect) and the firing rate of pacemaker cells (negative chronotropic effect).

In the kidney, antagonism of beta1-AR on juxtaglomerular cells suppresses the release of renin. This modulation reduces the activation of the renin-angiotensin-aldosterone system (RAAS), contributing to system-level physiological modulation that includes decreased cardiac output and a reduction in total peripheral resistance over time.

Dosage and Administration Information

Biprosol (Bisoprolol fumarate) is approved for oral administration and is generally taken once daily in the morning, which helps maintain consistent levels throughout the day. The tablets may be ingested with or without food and must be swallowed whole with liquid. Certain strengths are scored to allow for precise division necessary for titration regimens.

Official Dosing Regimens

The standard adult regimen differs by therapeutic context.

Indication Starting Dose (Once Daily) Typical Maintenance Dose Maximum Dose
Hypertension / Angina 5 mg 10 mg 20 mg
Chronic Heart Failure (CHF) 1.25 mg Up to 10 mg 10 mg

For Chronic Heart Failure, the treatment protocol involves a structured and gradual titration, where the initial 1.25 mg dose is typically doubled at approximately one-week intervals based on procedural tolerability, until the target maintenance dose is achieved.

Special Administration Instructions

Official instructions require specific procedural considerations for certain populations and when discontinuing use. For individuals with severe renal or hepatic impairment, the daily dose is generally restricted, and a lower starting dose is often specified. Furthermore, Biprosol is intended for long-term use and must not be stopped abruptly. Treatment cessation requires the dose to be slowly reduced (tapered) over a recommended period of one to two weeks, which is a critical procedural requirement. Use in pediatric patients is not recommended due to lack of official data.

Recent Clinical Evidence

Research evidence / Overview of studies for Biprosol

Evidence for Core Cardiovascular Uses

Research on Biprosol (Bisoprolol fumarate) was studied for use in people with stable Chronic Heart Failure (CHF), particularly in large Randomized, Double-Blind, Placebo-Controlled Trials. These studies primarily focused on measurements of survival outcomes and outcomes related to hospital admissions. The research describes patterns observed when these rates were compared to the placebo group. Research also examined patient-reported outcomes describing daily functioning or activity level. However, evidence is limited regarding optimal strategies for initiation in very advanced or unstable conditions.

Biprosol was evaluated in Controlled Trials for Hypertension (High Blood Pressure), where researchers primarily monitored changes in Systolic and Diastolic Blood Pressure (SBP/DBP). Studies describe consistent patterns of measurements recorded. Follow-up durations were limited in many of these trials, meaning there is limited information for long-term outcomes regarding cardiovascular events in people with uncomplicated hypertension.

Evidence for Symptom Management and Special Populations

The drug was studied for Chronic Stable Angina and for rate control in Atrial Fibrillation. For angina, studies researched examined patient-reported outcomes describing perceived discomfort. For Atrial Fibrillation, research focused on outcomes monitoring physiological strain or stress, such as changes in resting heart rate. Findings were mixed when comparing rate control to alternative strategies.

Research explored the use of Biprosol in different groups, including the elderly, where patterns appear similar to the general population. However, data for certain groups remain insufficient, such as pregnant women or the pediatric population. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Biprosol (FAQ)

Q: Is Biprosol considered a treatment for a long-term condition?

According to official product information, Biprosol is generally intended for long-term treatment, particularly for conditions like chronic heart failure. Official instructions indicate that Biprosol is typically not stopped abruptly, requiring healthcare professional supervision.

Q: How long does it typically take to notice the effects of Biprosol?

Regulatory information indicates that the concentration of Biprosol typically peaks in the blood within 2 to 4 hours after the first dose. However, the maximal therapeutic effect for managing blood pressure may take 2 to 6 weeks to fully stabilize.

Q: How will I know if Biprosol is having an effect?

The drug's intended effect is primarily assessed through clinical measurements, such as a reduced heart rate and lowered blood pressure. These measurable outcomes are assessed clinically by a healthcare professional.

Q: What is the typical time frame for using Biprosol?

For its approved cardiovascular uses, treatment with Biprosol is generally considered a long-term commitment. It is not intended for short-term or temporary use.

Q: How long does a single dose of Biprosol last in the body?

Biprosol is generally formulated for 24-hour therapeutic coverage, which supports the once-daily dosing regimen. This duration is supported by a plasma elimination half-life of approximately 9 to 12 hours.

Q: What are the signs that Biprosol is not working for a condition?

Lack of intended effect may be indicated by no change or a worsening of the symptoms of the condition being treated, such as uncontrolled high blood pressure or increased symptoms of heart failure.

Q: Can I take Biprosol at night instead of in the morning?

Biprosol tablets are generally recommended in official documents to be taken in the morning. Maintaining consistency by taking the medication at the same time every day is considered important.

Q: Can Biprosol be taken with food?

Yes, official product information states that Biprosol tablets may be ingested with or without food. Its absorption is not significantly affected by food intake.

Q: Can Biprosol be taken alongside common over-the-counter pain medications?

Regulatory warnings indicate that NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which include many common OTC pain relievers, can potentially reduce the blood pressure-lowering effect of Biprosol.

Q: Does Biprosol interact with alcohol?

Official patient guidance notes that consuming alcohol can increase the blood pressure-lowering effect of Biprosol. This interaction may be associated with an increased feeling of dizziness or lightheadedness.

Q: Is Biprosol listed as safe to take during pregnancy?

Regulatory information states that use during pregnancy is generally not recommended. Use is considered only when the potential benefit is judged to outweigh the potential risk, as animal studies have shown adverse effects on the fetus.

Q: Is Biprosol suitable for use in people with kidney impairment?

Official guidelines indicate that Biprosol can be used in people with kidney impairment. The dose may be restricted or require adjustment, particularly in cases of severe impairment.

Q: Can people with pre-existing heart conditions take Biprosol?

While Biprosol treats certain heart conditions, it is contraindicated (must not be used) in patients with specific severe heart problems. These include conditions like overt cardiac failure, cardiogenic shock, or certain types of marked sinus bradycardia.

Q: Does taking Biprosol require any routine blood work or medical monitoring?

Yes, close clinical monitoring of vital signs, such as heart rate and blood pressure, is recommended, especially during the initiation and dose adjustment phases. Some official information also advises regular blood tests to check kidney or liver function.

Q: Does Biprosol interact with common herbal supplements like St. John's Wort?

Official interaction guidance states that Biprosol may interact with strong CYP3A4 inducers. St. John's Wort is a known inducer of this enzyme, which could potentially alter the concentration of the drug in the body.

Q: What happens if Biprosol is stopped suddenly?

Abrupt discontinuation of Biprosol is associated with the risk of a worsening of the underlying heart condition. This includes the risk of cardiovascular events, such as the exacerbation of angina.

Q: Why is Biprosol a prescription-only medicine?

Biprosol is classified as a prescription-only medicine because it is used to manage serious cardiovascular conditions. Treatment requires careful medical monitoring, specialized dosing (titration), and clinical assessment of individual risks and benefits.

Q: Are there any specific activities or machinery to avoid while taking Biprosol?

Official patient warnings advise individuals to know how they react to Biprosol before attempting to drive or operate heavy machinery. This caution is advised because dizziness, lightheadedness, or tiredness are listed as possible effects of the drug.

How should Biprosol be stored and disposed of?

How to Store and Dispose of Biprosol?

Biprosol (bisoprolol fumarate) tablets require specific storage to maintain product stability and must be handled according to official disposal rules.

Storage Requirements

Requirement Official Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C), permitting excursions up to 30 C.
Protection Keep the container tightly closed and protect the tablets from excess moisture and light. Do not freeze.
Container Store in the original container in which it was dispensed.
Child Safety Must be kept out of the reach of children.

Disposal

Unused or expired Biprosol should be handled as pharmaceutical waste. Dispose of the product according to local regulations for proper collection and destruction. The medication should not be flushed down a toilet or drain unless specifically authorized by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Biprosol found in:

A-Z Index: